Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Serostim Market Size, Value And Growth Trajectory Through 2030
The historical growth can be attributed to the presence of recombinant somatropin formulations, enhanced management of HIV-associated wasting, broader access to antiretroviral therapy, greater clinical awareness of cachexia, and the emergence of specialized endocrinology treatments.
The anticipated growth during the forecast period is driven by an increasing emphasis on therapies that enhance quality of life, the rising adoption of supplementary HIV treatments, the expansion of home-based care delivery systems, a growing demand for metabolic support therapies, and advancements in long-acting hormone formulations. Concurrently, major trends expected in this period encompass a greater utilization of recombinant growth hormone therapies, an elevated focus on cachexia management, an increased emphasis on treatments for improving body composition, the widening of long-term hormone therapy programs, and enhanced monitoring of treatment results.
Get A Free Sample Report With In-Depth Market Insights:
Serostim Market Demand Drivers Opening New Revenue Streams
The increasing occurrence of hiv/aids is anticipated to fuel the expansion of the serostim market in the future. Hiv/aids, a viral infection, compromises the body’s immune defenses and can lead to acquired immunodeficiency syndrome (AIDS) if left untreated. The increasing prevalence of HIV/AIDS stems from contributors like unprotected sexual activity, insufficient healthcare accessibility, inadequate public understanding, and societal stigma and discrimination, all of which facilitate viral transmission. Serostim assists individuals with HIV/AIDS by fostering weight increase, boosting lean body mass, and enhancing physical robustness, effectively counteracting HIV-related wasting and elevating their general well-being. As an illustration, the UK Health Security Agency, a UK-based government body, reported in October 2024 that England observed 6,008 new HIV diagnoses in 2023, representing a 51% rise from the 3,975 diagnoses recorded in 2022. Consequently, the escalating incidence of hiv/aids is propelling the expansion of the serostim market.
Serostim Market Segment Outlook: Which Categories Are Growing Fastest?
The serostim market covered in this report is segmented –
1) By Indication: HIV-Associated Wasting Syndrome, Cachexia
2) By Distribution Channel: Direct Sales, Pharmacies, Wholesalers
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Serostim Market Leading Companies And Competitive Benchmarking
Major companies operating in the serostim market are EMD Serono Inc.
View The Full Serostim Market Report:
Serostim Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the serostim market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the serostim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
